29958537694: Difference between revisions
From Verified Handles
company
29958537694
29958537694
(UCB) |
(AB-V1) |
||
(7 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
{{DISPLAYTITLE:UCB}} | {{DISPLAYTITLE:UCB}} | ||
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small> | UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small> | ||
{| | {{SF| | ||
| | {{Twt|ucb_news}} | ||
{{Twt|UCBUSA}} | |||
{{Wb|http://www.ucb.com/|ucb.com}} | |||
}} | |||
{{IDF| | |||
| | {{Isni|000000012154737X}} | ||
}} | |||
{{VIAF|127775358}} | |||
| | |||
|} | |||
{{VHID|29958537694}}{{#subtitle: <big>company</big>}} | |||
{{#subtitle: <big>company</big>}} |
Latest revision as of 17:18, 27 February 2022
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. from Wikipedia
Icon | Service | Username | |
---|---|---|---|
![]() |
@ucb_news | ![]() | |
![]() |
@UCBUSA | ![]() | |
![]() |
Website | ucb.com | ![]() |
Additional identifiers
These are provided for reference and have been verified to be accurate.
Icon | Database | Identifier | |
---|---|---|---|
![]() |
ISNI | 000000012154737X | ![]() |